| Document |
Document Title |
|
JP6186010B2 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-19 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhi...
|
|
JP6155285B2 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-3 cycloalkenyl triterpenoids that possess unique antiviral activity are provided as HIV maturation i...
|
|
JP2017110012A |
To provide cardiogenin main isomer composition substantially free of minor isomers (hereinafter called isolated cardiogenin main isomer).A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from ...
|
|
JP2017513824A |
Five-ring triterpene compounds are provided herein. Similarly, a drug containing a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt or prodrug thereof, in combination with one or more pharmaceutical...
|
|
JP6129084B2 |
Disclosed herein are novel C4-monomethyl triterpenoid compounds and derivatives thereof, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufa...
|
|
JP6100786B2 |
Compounds of Formula I: that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.
|
|
JP6091520B2 |
The present invention relates to a compound characterized by the following Formula I: or a pharmaceutically acceptable salt thereof, wherein X, Y, and Z are as described herein. Compounds of the present invention are useful for the treat...
|
|
JP2016216364A |
To provide a novel bladder smooth muscle hypercontraction inhibitor.The invention provides a bladder smooth muscle hypercontraction inhibitor containing Elaeagnaceae Hippophae extract as an active ingredient, the Elaeagnaceae Hippophae e...
|
|
JP6043361B2 |
The present invention belongs to the field of natural medicine and pharmaceutical chemistry, and specifically relates to novel amidated derivatives of oleanolic acid according to formula (I) or a pharmaceutically acceptable salt thereof,...
|
|
JP6019021B2 |
This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, l...
|
|
JP6001560B2 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturat...
|
|
JP6000283B2 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-28 amines of C-3 modified betulinic acid derivatives that possess unique antiviral activity are prov...
|
|
JP5990160B2 |
The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolone methyl.
|
|
JP5972986B2 |
The present invention relates to polymorphic forms of the compound of Formula I (i.e., ethyl 2-cyano-3,12-dioxoIeana-1,9(11)-dien-28-oate (CDDO ethyl ester)) and methods of using them for treating a variety of disease states such as canc...
|
|
JP2016145212A |
To clarify a therapeutic potential of ethyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO ethyl ester), which is a triterpenoid compound.The present invention provides polymorphs of the triterpenoid compound represented by formula ...
|
|
JP5924634B2 |
It is intended to provide a method for producing aglycone from a glycoside efficiently at low cost without using an acid catalyst or an organic solvent. The method for producing aglycone, characterized by bringing a glycoside into contac...
|
|
JP2015164939A |
To provide crystalline forms of methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester, figure 1), which is a triterpenoid compound, possessing properties, such as greater aqueous solubility and chemical stability, that a...
|
|
JP2015527407A |
The present application is: (a) a compound of formula (I) and a salt thereof (Y and Z are as defined herein); (b) a composition comprising such a compound and salt; and (c). It relates to the use of such compounds, salts and compositions...
|
|
JP5778772B2 |
The invention relates to a method for preparing a refined extract of Centella asiatica comprising a mixture of madecassoside and terminoloside. The method comprises: passage over adsorbent resin; elution with an eluent comprising at leas...
|
|
JP2015151387A |
To provide a lipolysis inhibitor and a stomach cancer cell proliferation inhibitor derived from Camellia sinensis (L.) Kuntze var. assamica Kitam. flower part, and to provide a novel saponin compound obtained by separating and purifying ...
|
|
JP5755731B2 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 and C-28 betulinic acid derivatives that possess unique antiviral activity are provided a...
|
|
JP2015134793A |
To provide a saponin compound analogous to QS-21 currently favored in anticancer and antiviral vaccines.This invention relates to a compound represented by a formula X, where ^^^ is a single bond or a double bond; W is Me, -CHO or the li...
|
|
JP5752789B2 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 betulinic acid and other structurally related natural products derivatives that possess u...
|
|
JP5706815B2 |
The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin ...
|
|
JP5706926B2 |
The invention concerns compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium. The invention also concerns methods for obtaining said compounds, screening methods capable of sele...
|
|
JP2015028019A |
To provide compounds and methods for the treatment and prevention of diseases such as those associated with oxidative stress and inflammation.This invention provides, for example, a compound of the formula, wherein Ris a hydroxy group, a...
|
|
JP5665276B2 |
An agent for preventing or ameliorating skin aging, which exhibits a more excellent effect on the suppression of formation, or the amelioration, of wrinkles on the skin or sagging skin. An agent for preventing or ameliorating skin aging,...
|
|
JP5658238B2 |
A compound represented by formula II, a preparation method, and uses thereof in treating liver damage and inflammation and so on are disclosed. A method for preparing glycyrrhetinic acid derivatives are also disclosed. In the compound re...
|
|
JP5610766B2 |
The present invention relates to novel derivatives of glycyrrhetinic acid, compositions comprising said derivatives and their use in the treatment of conditions or diseases that benefits from an upregulation of PPARgamma and/or a downreg...
|
|
JP5604077B2 |
|
|
JP5588966B2 |
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising suc...
|
|
JP2014152171A |
To provide a new triterpene compound having both high antitumor activity and multiple drug resistance inhibitory activity, to provide a method of producing the same, and to provide an antitumor active agent having multiple drug resistanc...
|
|
JP5566392B2 |
The invention describes novel triterpenoid 2-deoxy glycosides of general formula I, wherein at least one of the substituents X1 and R2 contains a 2-deoxy glycosidic group, method of preparation thereof, their cytotoxic activity and a pha...
|
|
JP5548874B2 |
To provide a medicine for overcoming a cancer immunosuppressive state, a composition for cancer immuno-therapy using the medicine and cancer immuno-therapy.A weaning agent for cancer immunosuppression includes betulin as an effective com...
|
|
JP5539224B2 |
A highly pure asiaticoside and a pharmaceutical grade asiatic acid can be prepared, along with salts of asiatic acid, for use in formulating therapeutic compositions that are suitable for treating arthritis, psoriasis and other inflammat...
|
|
JP5529850B2 |
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising suc...
|
|
JP5529851B2 |
This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula:wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such...
|
|
JP5487947B2 |
|
|
JP5460840B2 |
|
|
JP5455505B2 |
|
|
JP5428000B2 |
|
|
JP5425799B2 |
The invention discloses water-soluble triterpenephenol compounds having antitumor activity represented by formula (I), wherein the substituents R 1 ˆ¼R 4 and M are defined as in the description. The invention also discloses a method fo...
|
|
JP2014500328A |
A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ colum...
|
|
JP2013545815A |
Provided herein are inhibitors of CYP11B, CYP17, and/or CYP21 enzymes of Formula Z, IX, X, XI, XII, XIII, XIV, XV, XVI, or XVII. Also described herein are pharmaceutical compositions that include at least one compound described herein an...
|
|
JP5345933B2 |
The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock.
|
|
JP5339340B2 |
To provide an aqueous solution that contains highly pure saponin of good quality in a high concentration extracted from strained lees of camellia seeds, as a means of more effectively making use of strained lees of camellia seeds. The aq...
|
|
JP2013536203A |
Chemical entities which are triterpenoid derivatives, pharmaceutical compositions and methods of treatment of inflammatory, neurodegenerative, neoplastic and autoimmune diseases are described.
|
|
JP5286087B2 |
The present invention relates to the field of a medicine for treating diseases associated with inflammation, immunity or infection, and in particular, to glycyrrhetinic acid-30-amide derivatives of general formula I and their preparation...
|
|
JP5275678B2 |
To provide a new application of an extract of tea flower and/or a new saponin compound contained therein or its salt. The present invention provides a composition for preventing and improving bowel obstruction and constipation or a free ...
|
|
JP5258261B2 |
|
